Mainstream

M&A Snapshot: Novartis to buy Tourmaline Bio for $1.4B, citing promise of heart drug pacibekitug

M&A Snapshot: Novartis to buy Tourmaline Bio for $1.4B, citing promise of heart drug pacibekitug

Post Contentnvs, trmlRead More

You might also be interested in reading Stellantis expects H1 loss of $2.7B on tariffs, production delays.

September 9, 2025
In Mainstream